Clinical Trial Update: A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

View source ↗

Summary

A completed non-interventional study evaluating real-world outcomes of first-line treatment options for HR-positive, HER2-negative locally advanced or metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Ribociclib (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Status: COMPLETED